Bioavailability of BMS-626529 in Healthy Subjects From Prototype Low Dose Extended Release Formulations (Part 1) and Prototype Extended Release Multi-particulate Formulations (Part 2) of BMS-663068 Relative to 600 mg Extended Release Tablet
- First Posted Date
- 2015-07-24
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 27
- Registration Number
- NCT02508064
- Locations
- π¬π§
GSK Investigational Site, Nottingham, United Kingdom
A Open-label, Drug-Drug Interaction With Maraviroc (DDI)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-06-25
- Last Posted Date
- 2017-09-25
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 112
- Registration Number
- NCT02480894
- Locations
- πΊπΈ
GSK Investigational Site, San Antonio, Texas, United States
A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers (DDI)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-06-25
- Last Posted Date
- 2017-07-27
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 26
- Registration Number
- NCT02480881
- Locations
- πΊπΈ
GSK Investigational Site, San Antonio, Texas, United States
Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers
- First Posted Date
- 2015-06-23
- Last Posted Date
- 2020-06-22
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 19
- Registration Number
- NCT02478463
- Locations
- πΊπΈ
GSK Investigational Site, Pittsburgh, Pennsylvania, United States
Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-06-23
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 102
- Registration Number
- NCT02478632
- Locations
- π¬π§
GSK Investigational Site, London, United Kingdom
Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Compared to Healthy Subjects
- First Posted Date
- 2015-06-10
- Last Posted Date
- 2017-09-25
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 52
- Registration Number
- NCT02467335
- Locations
- πΊπΈ
GSK Investigational Site, Hamilton, New Jersey, United States
Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1)
- First Posted Date
- 2015-04-29
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 510
- Registration Number
- NCT02429791
- Locations
- π¬π§
GSK Investigational Site, Manchester, United Kingdom
Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)
- First Posted Date
- 2015-04-21
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 518
- Registration Number
- NCT02422797
- Locations
- π¬π§
GSK Investigational Site, London, United Kingdom
Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2015-04-14
- Last Posted Date
- 2018-09-19
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 210
- Registration Number
- NCT02415595
- Locations
- π¬π§
GSK Investigational Site, Tooting, London, United Kingdom
Effect of Rifampin (RIF) on the Pharmacokinetics (PK) of Oral Cabotegravir (CAB) in Healthy Subjects
- First Posted Date
- 2015-04-08
- Last Posted Date
- 2016-01-06
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 15
- Registration Number
- NCT02411435
- Locations
- πΊπΈ
GSK Investigational Site, Overland Park, Kansas, United States
Β© Copyright 2024. All Rights Reserved by MedPath